GlassScriptPhysician profile
Shawn Tsekhan
NPI 1639466998
$5,050.16
in general payments reported to CMS, 2019-2025
33 companies · $1,533 in 2025
The $1,533 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.42 · 2020: $118 · 2021: $200 · 2022: $572 · 2023: $1,061 · 2024: $1,546 · 2025: $1,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,096 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24.36 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,095.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24.36 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,275.20 | 2021-2025 | Qulipta, Ubrelvy |
| Lundbeck LLC | $354.02 | 2020-2025 | Vyepti, Rexulti |
| Celgene Corporation | $314.86 | 2021-2024 | Zeposia |
| Amneal Pharmaceuticals LLC | $293.98 | 2022-2025 | Ongentys, Crexont, Ongentys 50mg Capsules 30 |
| Ucb, INC. | $269.19 | 2023-2025 | Rystiggo, Fintepla, Zilbrysq |
| Lilly USA, LLC | $236.27 | 2020-2025 | Emgality, Kisunla, Reyvow |
| Biogen, INC. | $228.09 | 2020-2025 | Vumerity |
| Pfizer INC. | $218.05 | 2023-2025 | |
| Eisai INC. | $201.58 | 2021-2025 | Leqembi |
| Argenx US, INC. | $165.17 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $147.74 | 2023-2025 | Nuplazid |
| Acorda Therapeutics, INC | $137.68 | 2019-2024 | Inbrija |
| Otsuka America Pharmaceutical, INC. | $128.51 | 2024-2025 | Rexulti, Nuedexta |
| Mdd US Operations, LLC | $114.09 | 2024-2025 | Gocovri |
| Neurocrine Biosciences, INC. | $113.60 | 2024-2025 | Ingrezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $108.89 | 2022 | |
| Tanabe Pharma America, INC. | $94.80 | 2022-2024 | |
| Sk Life Science, INC. | $79.42 | 2024 | |
| Grifols USA, LLC | $74.63 | 2023-2024 | Gamunex-C, Xembify |
| Allergan, INC. | $57.02 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $56.38 | 2021-2025 | Wainua |
| Merz Pharmaceuticals, LLC | $53.46 | 2025 | Xeomin |
| Genzyme Corporation | $52.12 | 2022 | |
| Kyowa Kirin, INC. | $42.43 | 2020-2024 | Nourianz |
| Csl Behring | $36.07 | 2023-2024 | Kcentra, Hizentra |
| Janssen Biotech, INC. | $35.67 | 2025 | |
| Vanda Pharmaceuticals INC. | $35.64 | 2024 | Ponvory |
| Neurelis, INC. | $31.66 | 2023 | Valtoco |
| Supernus Pharmaceuticals, INC. | $21.66 | 2020 | |
| Medtronic, INC. | $21.11 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $17.15 | 2023 | Relyvrio |
| Novartis Pharmaceuticals Corporation | $17.06 | 2024 | |
| Avion Pharmaceuticals | $16.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Tsekhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.